Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) Major Shareholder Braden Michael Leonard Purchases 29,600 Shares

Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) major shareholder Braden Michael Leonard bought 29,600 shares of the firm’s stock in a transaction on Tuesday, September 24th. The stock was acquired at an average cost of $1.41 per share, with a total value of $41,736.00. Following the transaction, the insider now owns 3,388,649 shares in the company, valued at approximately $4,777,995.09. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Braden Michael Leonard also recently made the following trade(s):

• On Tuesday, September 17th, Braden Michael Leonard acquired 55,300 shares of Reneo Pharmaceuticals stock. The shares were bought at an average price of $1.36 per share, for a total transaction of $75,208.00.
• On Tuesday, August 13th, Braden Michael Leonard bought 171,339 shares of Reneo Pharmaceuticals stock. The shares were bought at an average price of $1.39 per share, with a total value of $238,161.21.

Reneo Pharmaceuticals Price Performance

Shares of RPHM traded up $0.09 during trading hours on Thursday, hitting $1.62. The stock had a trading volume of 255,656 shares, compared to its average volume of 247,894. The firm has a market capitalization of $53.97 million, a PE ratio of -0.79 and a beta of 0.19. Reneo Pharmaceuticals, Inc. has a 12 month low of $0.98 and a 12 month high of $9.21. The stock has a fifty day moving average price of $1.46 and a 200 day moving average price of $1.59.

Reneo Pharmaceuticals (NASDAQ:RPHM) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.01. As a group, analysts anticipate that Reneo Pharmaceuticals, Inc. will post -0.65 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in RPHM. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Reneo Pharmaceuticals during the 2nd quarter valued at $27,000. Jump Financial LLC bought a new stake in Reneo Pharmaceuticals during the fourth quarter valued at about $41,000. Pale Fire Capital SE increased its position in Reneo Pharmaceuticals by 102.7% in the fourth quarter. Pale Fire Capital SE now owns 30,100 shares of the company’s stock worth $48,000 after buying an additional 15,249 shares in the last quarter. Marquette Asset Management LLC bought a new position in shares of Reneo Pharmaceuticals in the first quarter worth about $122,000. Finally, Vestal Point Capital LP bought a new position in shares of Reneo Pharmaceuticals in the fourth quarter worth about $640,000. 90.98% of the stock is currently owned by institutional investors.

About Reneo Pharmaceuticals

Reneo Pharmaceuticals, Inc, a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. The company's lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders.